In September 2018, following its approval by the FDA for rare types of childhood epilepsy, Epidiolex was rescheduled (by the Drug Enforcement Administration) as a Schedule V drug to allow for its prescription use. This change applies only to FDA-approved products containing no more than 0.1 percent THC. This allows GW Pharmaceuticals to sell Epidiolex, but it does not apply broadly and all other CBD-containing products remain Schedule I drugs. Epidiolex still requires rescheduling in some states before it can be prescribed in those states.
Hemp and Marijuana come form the same plant family, but are completely different in function, cultivation and application. Marijuana generally has a high level of THC (a psychoactive compound that makes you feel “high”) and is used for medicinal or recreational purpose. Hemp contains a negligible amount of THC (but is high in CBD) and is used in dietary supplements, skin products, clothing and paper.
I recommend CBD International to everyone I know who is fighting cancer including the Hospice team taking care of my daughter. All the different nurses always ask, they have many patients asking. If I can save anyone the three months it took me to find you, that time saved could save a life. When you find yourself in a situation like a cancer diagnosis, you are searching for something to help, you really don't know what you are getting. My visits to the medical marijuana shops in Southern California left me frustrated, they are not knowledgeable and kept steering me to edibles and hash oil and trying to find the correct treatment was for me, about the only thing I could do for my daughter that might help her and the only thing she was willing to try. From the very first contact on your website, to the questionnaire to all correspondence, so timely and the integrity and kindness you and your company have shown me, I can't praise you enough. You guys are the real deal.
The endocannabinoid system is tonically active in control of pain, as demonstrated by the ability of SR141716A (rimonabant), a CB1 antagonist, to produce hyperalgesia upon administration to mice (Richardson et al 1997). As mentioned above, the ECS is active throughout the neuraxis, including integrative functions in the periacqueductal gray (Walker et al 1999a; Walker et al 1999b), and in the ventroposterolateral nucleus of the thalamus, in which cannabinoids proved to be 10-fold more potent than morphine in wide dynamic range neurons mediating pain (Martin et al 1996). The ECS also mediates central stress-induced analgesia (Hohmann et al 2005), and is active in nociceptive spinal areas (Hohmann et al 1995; Richardson et al 1998a) including mechanisms of wind-up (Strangman and Walker 1999) and N-methyl-D-aspartate (NMDA) receptors (Richardson et al 1998b). It was recently demonstrated that cannabinoid agonists suppress the maintenance of vincristine-induced allodynia through activation of CB1 and CB2 receptors in the spinal cord (Rahn et al 2007). The ECS is also active peripherally (Richardson et al 1998c) where CB1 stimulation reduces pain, inflammation and hyperalgesia. These mechanisms were also proven to include mediation of contact dermatitis via CB1 and CB2 with benefits of THC noted systemically and locally on inflammation and itch (Karsak et al 2007). Recent experiments in mice have even suggested the paramount importance of peripheral over central CB1 receptors in nociception of pain (Agarwal et al 2007)